# EDGAR Filing Document

**Accession Number:** 0001173281
**File Stem:** 0001104659-23-038395
**Filing Date:** 2023-3
**Character Count:** 9185
**Document Hash:** 2d29b77e06d2324feac82170223b73dd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-038395.hdr.sgml**: 20230329

**ACCESSION NUMBER**: 0001104659-23-038395

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230329

**ITEM INFORMATION**: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

**FILED AS OF DATE**: 20230329

**DATE AS OF CHANGE**: 20230329

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NeuBase Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001173281
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 465622433
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35963
- **FILM NUMBER:** 23776042

**BUSINESS ADDRESS:**
- **STREET 1:** 350 TECHNOLOGY DRIVE
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15219
- **BUSINESS PHONE:** 412-763-3350

**MAIL ADDRESS:**
- **STREET 1:** 350 TECHNOLOGY DRIVE
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15219

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ohr Pharmaceutical Inc
- **DATE OF NAME CHANGE:** 20090819

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BBM HOLDINGS, INC.
- **DATE OF NAME CHANGE:** 20070402

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRIME RESOURCE INC
- **DATE OF NAME CHANGE:** 20020513

?xml version="1.0" encoding="utf-8"?

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 29, 2023

**<u>NeuBase Therapeutics, Inc.</u>**

(Exact Name of Registrant as Specified in Its Charter)

<u>Delaware</u> <u>001-35963</u> <u>46-5622433</u> <br> (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

<u>350 Technology Drive, Pittsburgh, PA</u> <u>15219</u> <br> (Address of Principal Executive Offices) (Zip Code)

<u>(412) 763-3350</u> <br> (Registrant's Telephone Number, Including Area Code)

<u>N/A</u> <br> (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | NBSE | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**

As previously reported, on September 29, 2022, NeuBase Therapeutics, Inc. (the "Company") received a letter (the "Notice") from The Nasdaq Stock Market ("Nasdaq") notifying the Company that, because the closing bid price for its common stock had been below $1.00 per share for 30 consecutive business days, it no longer complied with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share (the "Minimum Bid Price Requirement"), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive business days. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial compliance period of 180 calendar days, or until March 28, 2023 to regain compliance with the Minimum Bid Price Requirement.

On March 29, 2023, Nasdaq notified the Company in writing that while the Company had not regained compliance with the Minimum Bid Price Requirement, it was eligible for an additional 180 calendar day period, or until September 25, 2023, to regain compliance with the Minimum Bid Price Requirement. Nasdaq's determination was based on the Company having met the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and on the Company's written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, including by effecting a reverse stock split, if necessary. If at any time during this additional time period the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation of compliance and the matter will be closed. During the additional compliance period, the Company's shares of common stock will continue to be listed and traded on The Nasdaq Capital Market.

If the Company does not demonstrate compliance by September 25, 2023, Nasdaq will provide written notice that the Company's common stock will be delisted, at which point the Company may appeal Nasdaq's determination to a Hearings Panel. The Company would remain listed on Nasdaq pending the Hearings Panel's decision. There can be no assurance that, in the event the Company does not regain compliance within the requisite time period and the Company appeals the delisting determination by Nasdaq to the Hearings Panel, such appeal would be successful.

The Company intends to actively monitor the bid price for its common stock between now and September 25, 2023 and will consider available options to regain compliance with the Minimum Bid Price Requirement, including the implementation of a reverse stock split, if necessary. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or that the Company will otherwise be in compliance with the other listing standards for The Nasdaq Capital Market.

***Forward-Looking Statements***

Except for the factual statements made herein, information contained in this Current Report on Form 8-K consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects or future events, as well as words such as "believes," "intends," "expects," "plans" and similar expressions, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. For example, there can be no assurance that the Company will meet the Minimum Bid Price Requirement during any compliance period or otherwise in the future, otherwise meet Nasdaq compliance standards, or that Nasdaq will grant the Company any relief from delisting as necessary or whether the Company can agree to or ultimately meet applicable Nasdaq requirements for any such relief. Reference is also made to other factors detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. The forward-looking statements contained in this Current Report on Form 8-K speak only as of the date of this Current Report on Form 8-K and the Company assumes no obligation to publicly update any forward-looking statements to reflect changes in information, events or circumstances after the date of this Current Report on Form 8-K, unless required by law.

<u>SIGNATURE</u>

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | NEUBASE THERAPEUTICS, INC. <br> (Registrant) | NEUBASE THERAPEUTICS, INC. <br> (Registrant) |
| Date: March 29, 2023 | By: | /s/ Todd P. Branning |
|  |  | Todd P. Branning |
|  |  | Chief Financial Officer |

---